Clinical Trial Update: Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and preliminary efficacy of the combination of blinatumomab and pembrolizumab in adults with relapsed or refractory diffuse …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Blinatumomab (blinatumomab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Amgen | Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Status: COMPLETED | Results posted: 2022-02-25